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background: Cardiovascular (CV) outcomes in atrial fibrillation (AF) patients (pts) in the AFFIRM trial differed based on initial antiarrhythmic drug 
(AAD) selection but the uniformity of this finding in AF subgroups is unclear.
methods: We examined the CV outcomes of AF pts with thyroid disease based on the initial AAD selected in the Rhythm arm with propensity score 
matched AF pt subgroups from the Rate arm. Amiodarone (Amio), Sotalol (Sot) & Type 1C (flecainide & propafenone) pts were compared to matched 
Rate pts. Endpoints studied were CV hospitalizations (CVH) & death (D).
results: 202 pts with thyroid disease received AADs in the Rhythm arm. 75 of 729 Amio pts, 77 of 606 Sot pts & 50 of 268 IC pts had thyroid 
disease & were matched with propensity score matched gps from the Rate arm. CVH & D were comparable for the thyroid pts compared to the entire 
Rate cohort but demonstrated increased risk with Amio (Hazard Ratio{HR}:1.75 (95% Confidence intervals {CI} 1.17, 2.62,p=0.006) & Sot (HR:1.80 
(CI 1.15, 2.80, p=0.01). CVH were also more common with Amio (HR=2.08, CI1.35,3.21, p=0.001) & Sot (HR=1.69, CI 1.05,2.72, p=0.031) (Figure) 
but mortality was comparable.
conclusions: 1. Thyroid disease alone is not associated with increased risk ofCVH & D.in pts with AF 2. Initial administration of Amio & Sot in these 
pts increases risk of CVH compared to Rate.3. Prospective studies examining efficacy, CV outcomes & safety of these AADs in AF pts with thyroid 
disease are warranted.
